stockrowGuardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
Follow GH
Alert me
Guardant Health, Inc. (GH) Return on equity
Guardant Health, Inc.'s return on equity over the twelve months to 30 September 2026 was 153.9%, down 194.5 percentage points from fiscal 2025 (348.4%). Over the past ten years it has ranged from −4,584.5% (fiscal 2024) to 348.4% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 348.4% | 4,932.92 |
| FY2024 | −4,584.5% | (4,146.37) |
| FY2023 | −438.1% | (252.48) |
| FY2022 | −185.7% | (143.90) |
| FY2021 | −41.8% | (17.54) |
| FY2020 | −24.2% | (12.40) |
| FY2019 | −11.8% | 46.50 |
| FY2018 | −58.3% | (119.40) |
| FY2017 | 61.1% | 29.38 |
| FY2016 | 31.7% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. | 153.9% |
| MEDP Medpace Holdings, Inc. compare | 117.9% |
| ILMN Illumina, Inc. compare | 32.4% |
| DGX Quest Diagnostics Incorporated compare | 14.8% |
| LH Labcorp Holdings Inc. compare | 11.5% |
| ICLR ICON PLC compare | 4.86% |
| CRL Charles River Laboratories International, Inc. compare | 1.21% |
| RVTY Revvity Inc. compare | 0.00% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on GH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement